349 related articles for article (PubMed ID: 28150022)
21. Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery.
AlGizawy SM; Essa HH; Ahmed BM
Oncologist; 2015 Jul; 20(7):752-7. PubMed ID: 26040621
[TBL] [Abstract][Full Text] [Related]
22. A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer.
Hasegawa S; Goto S; Matsumoto T; Hida K; Kawada K; Matsusue R; Yamaguchi T; Nishitai R; Manaka D; Kato S; Kadokawa Y; Yamanokuchi S; Kawamura J; Zaima M; Kyogoku T; Kanazawa A; Mori Y; Kanai M; Matsumoto S; Sakai Y
Ann Surg Oncol; 2017 Nov; 24(12):3587-3595. PubMed ID: 28685354
[TBL] [Abstract][Full Text] [Related]
23. A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer.
Toritani K; Watanabe J; Suwa Y; Nakagawa K; Suwa H; Ishibe A; Ota M; Kunisaki C; Yamanaka T; Endo I
Int J Colorectal Dis; 2020 Dec; 35(12):2197-2204. PubMed ID: 32725346
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
Wein A; Riedel C; Brückl W; Merkel S; Ott R; Hanke B; Baum U; Fuchs F; Günther K; Reck T; Papadopoulos T; Hahn EG; Hohenberger W
Oncology; 2003; 64(2):131-8. PubMed ID: 12566910
[TBL] [Abstract][Full Text] [Related]
25. Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study.
Ichikawa N; Homma S; Funakoshi T; Hattori M; Sato M; Kamiizumi Y; Omori K; Nomura M; Yokota R; Koike M; Kon H; Takeda K; Ishizu H; Hirose K; Kuraya D; Ishikawa T; Murata R; Iijima H; Kawamata F; Yoshida T; Ohno Y; Minagawa N; Takahashi N; Taketomi A
Surg Today; 2019 Aug; 49(8):712-720. PubMed ID: 30838443
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Schrag D; Weiser MR; Goodman KA; Gonen M; Hollywood E; Cercek A; Reidy-Lagunes DL; Gollub MJ; Shia J; Guillem JG; Temple LK; Paty PB; Saltz LB
J Clin Oncol; 2014 Feb; 32(6):513-8. PubMed ID: 24419115
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases.
Hasegawa H; Watanabe M; Baba H; Yoshinare K; Mukai M; Kubota T; Kitajima M
Hepatogastroenterology; 2002; 49(46):891-3. PubMed ID: 12143234
[TBL] [Abstract][Full Text] [Related]
28. Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: preliminary results.
Tjandra JJ; Reading DM; McLachlan SA; Gunn IF; Green MD; McLaughlin SJ; Millar JL; Pedersen JS
Dis Colon Rectum; 2001 Aug; 44(8):1113-22. PubMed ID: 11535850
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study.
Lee WS; Baek JH; Shin DB; Sym SJ; Kwon KA; Lee KC; Lee SH; Jung DH
Int J Clin Oncol; 2013 Apr; 18(2):260-6. PubMed ID: 22350021
[TBL] [Abstract][Full Text] [Related]
30. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
31. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M;
Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228
[TBL] [Abstract][Full Text] [Related]
32. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E
Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606
[TBL] [Abstract][Full Text] [Related]
33. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Konishi T; Shinozaki E; Murofushi K; Taguchi S; Fukunaga Y; Nagayama S; Fujimoto Y; Akiyoshi T; Nagasaki T; Suenaga M; Chino A; Kawachi H; Yamamoto N; Ishikawa Y; Oguchi M; Ishizuka N; Ueno M; Yamaguchi K
Ann Surg Oncol; 2019 Aug; 26(8):2507-2513. PubMed ID: 30963400
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
[TBL] [Abstract][Full Text] [Related]
36. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
Rödel C; Liersch T; Hermann RM; Arnold D; Reese T; Hipp M; Fürst A; Schwella N; Bieker M; Hellmich G; Ewald H; Haier J; Lordick F; Flentje M; Sülberg H; Hohenberger W; Sauer R
J Clin Oncol; 2007 Jan; 25(1):110-7. PubMed ID: 17194912
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K
J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343
[TBL] [Abstract][Full Text] [Related]
38. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
Ishii Y; Hasegawa H; Endo T; Okabayashi K; Ochiai H; Moritani K; Watanabe M; Kitagawa Y
Eur J Surg Oncol; 2010 Nov; 36(11):1061-5. PubMed ID: 20538422
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
[TBL] [Abstract][Full Text] [Related]
40. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
Zhang MX; Li XB; Guan BJ; Guan GX; Lin XY; Wu XD; Chi P; Xu BH
BMJ Open; 2019 Mar; 9(3):e025944. PubMed ID: 30904869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
